TY - T1的阶段时淀粉样病变对血管性认知障碍患者的临床表型(P2.099) JF -神经学乔-神经学六世- 88 - 16补充SP - P2.099 AU -大卫Bergeron盟-尼尔斯普林斯盟-科林Groot盟-安妮塔·Loenhoud盟-罗伯特•Laforce 首页Jr . AU - Bart van Berckel盟Frederic Barkhof盟Wiesje van der传单AU -菲利普Scheltens盟里克Ossenkoppele Y1 - 2017/04/18 UR - //www.ez-admanager.com/content/88/16_Supplement/P2.099.abstract N2 -目的:研究阶段时淀粉样蛋白在临床病理学的影响,神经心理学和神经功能的患者血管认知impairmentBackground:脑血管疾病是一个重要的认知障碍和痴呆的原因,和血管性认知障碍(VCI)在概念上不同于阿尔茨海默病(AD)。然而,脑血管和淀粉样病变可能共存,特别是老年患者。淀粉样β蛋白生物标志物可以检测淀粉样蛋白体内病理。我们的目的是调查阶段的影响淀粉样病变的临床表型的VCI患者。设计/方法:从阿姆斯特丹痴呆我们包括了218例VCI患者队列实现2014年VASCOG标准(V +)。作为一个参照组,我们包括120名患者。所有的受试者都接受的诊断检查包括大脑核磁共振和腰椎穿刺。我们定义的淀粉样病变(+)脑脊液Abeta-42 & lt; 638 ng / L。这导致116 + V +动+ 102,+ 120 V−病人。我们使用线性回归分析比较MMSE分数,z得分为神经心理学测试性能和神经精神库存的分数(NPI),调整了年龄、性别和教育。结果:表给出了根据研究小组主题特点。 Amyloid-negative VCI patients were younger than those who were amyloid-positive. Mean MMSE scores did not differ between study groups. Greatest memory impairment was found in the A+V− group (p<0.05). In VCI patients (V+), co-morbid amyloid-positivity was associated with worse memory performance (A+V+<A−V+, p<0.05). Conversely, amyloid-negative VCI patients had greater attentional and executive deficits (A+V+<A−V+, p<0.05), as well as higher NPI scores (A−V+ [15.3±14.0] > A+V+ [9.8±10.5]; p<0.05).Conclusions: VCI patients show greater attentional and executive dysfunction but less memory dysfunction than patients with AD. Within VCI patients, co-morbid amyloid pathology is associated with worse memory function, while the absence of amyloid pathology is associated with greater attentional dysfunction and more severe neuropsychiatric symptomatology.Disclosure: Dr. Bergeron has nothing to disclose. Dr. Prins has nothing to disclose. Dr. Groot has nothing to disclose. Dr. van Loenhoud has nothing to disclose. Dr. Laforce has received personal compensation for activities with Eli Lilly Canada Inc. as a member of the scientific advisory board. Dr. van Berckel has nothing to disclose. Dr. Barkhof has received personal compensation for activities with Bayer Schering Pharma, Biogen Idec, Sanofi Genzyme, Janssen Research, Merck Serono, Novartis, Roche, Synthon BV, and Teva Neuroscience as a consultant or a speaker. Dr. van der Flier has nothing to disclose. Dr. Scheltens has received support from Merck, GE Healthcare and Piramal. Dr. Ossenkoppele has nothing to disclose. ER -